Acumen Pharmaceuticals, Inc. Common Stock (ABOS) is a publicly traded Healthcare sector company. As of May 21, 2026, ABOS trades at $2.37 with a market cap of $157.46M and a P/E ratio of -1.16. ABOS moved +9.22% today. Year to date, ABOS is +18.69%; over the trailing twelve months it is +121.70%. Its 52-week range spans $0.86 to $3.60. Analyst consensus is buy with an average price target of $8.00. Rallies surfaces ABOS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies organizes ABOS SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
| Metric | Value |
|---|---|
| Price | $2.37 |
| Market Cap | $157.46M |
| P/E Ratio | -1.16 |
| EPS | $-2.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $3.60 |
| 52-Week Low | $0.86 |
| Volume | 1.40K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-121.33M |
| Gross Margin | 0.00% |
2 analysts cover ABOS: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $8.00.